Disclosure Insight Maintains Medium Risk Rating on Luminex

A report from D.I. reiterates its Medium Risk Positive Bias rating on Luminex (NASDAQ: LMNX).

The report states, “Concentrated revenue supports our opinion of a Medium Risk - Positive Bias rating for LMNX. In 2010, One Lambda and Bio-Rad Laboratories accounted for 16% and 13% of total revenue, respectively. Two unnamed customers accounted for 25% and 9% of revenue during 9M11.”

LMNX closed yesterday at $19.31.